Scientific Advisors/Consultant
-
Dr. Rasmus Jorgensen
Scientific consultant of Prosit Sole
CEO & Founder of Cytoki Phrama
Former VP of Novo Nordisk Denmark and in Novo Nordisk China
Rasmus Jorgensen is the CEO and Founder of CytoKi Pharma. He has 15+ years of experience in Biotech and Pharma, including VP positions in Novo Nordisk Denmark and in Novo Nordisk China. He has been involved in progressing multiple projects through pre-clinical to clinical development. Also deeply involved in licensing deals and running partnerships. As the CEO he brings a strong and proven track record in driving innovation, research strategy, organizations, external collaborations and licensing deals
Scientific consultant of Prosit Sole
CEO & Founder of Cytoki Phrama
Former VP of Novo Nordisk Denmark and in Novo Nordisk China
Rasmus Jorgensen is the CEO and Founder of CytoKi Pharma. He has 15+ years of experience in Biotech and Pharma, including VP positions in Novo Nordisk Denmark and in Novo Nordisk China. He has been involved in progressing multiple projects through pre-clinical to clinical development. Also deeply involved in licensing deals and running partnerships. As the CEO he brings a strong and proven track record in driving innovation, research strategy, organizations, external collaborations and licensing deals
-
Dr. Megan Baldridge
MD, PhD
Washington University in St. Louis · Division of Infectious Diseases, Department of Medicine
Principal Investigator
Who firstly set up the Norovirus infectious model in mouse.
Molecular Microbiology and Microbial Pathogenesis Program
Molecular Genetics and Genomics Program
Immunology Program
Computational and Systems Biology Program
Dr. Megan Baldridge is an Assistant Professor in the Division of Infectious Diseases and the Edison Family Center for Genome Sciences & Systems Biology at Washington University School of Medicine in St. Louis. Dr. Baldridge firstly in the world set up the Norovirus infectious model in mouse. She completed her MD/PhD training at Baylor College of Medicine, studying the effects of interferon-gamma on hematopoietic stem cells in the lab of Dr. Margaret Goodell, then during her postdoc explored the interactions between norovirus, intestinal bacteria, and host antiviral signaling molecule interferon-lambda in the lab of Dr. Herbert ‘Skip’ Virgin. Dr. Baldridge started her lab in 2016, and has received a Kenneth Rainin Foundation Innovator Award and a Pew Biomedical Scholar Award for her continued work on the influence of the microbiota on viral infection. Her lab now focuses on the role of the microbiota in regulating infection by enteric viruses norovirus and rotavirus, as well as in modulating mucosal vaccine responses to rotavirus and HIV vaccines.
MD, PhD
Washington University in St. Louis · Division of Infectious Diseases, Department of Medicine
Principal Investigator
Who firstly set up the Norovirus infectious model in mouse.
Molecular Microbiology and Microbial Pathogenesis Program
Molecular Genetics and Genomics Program
Immunology Program
Computational and Systems Biology Program
Dr. Megan Baldridge is an Assistant Professor in the Division of Infectious Diseases and the Edison Family Center for Genome Sciences & Systems Biology at Washington University School of Medicine in St. Louis. Dr. Baldridge firstly in the world set up the Norovirus infectious model in mouse. She completed her MD/PhD training at Baylor College of Medicine, studying the effects of interferon-gamma on hematopoietic stem cells in the lab of Dr. Margaret Goodell, then during her postdoc explored the interactions between norovirus, intestinal bacteria, and host antiviral signaling molecule interferon-lambda in the lab of Dr. Herbert ‘Skip’ Virgin. Dr. Baldridge started her lab in 2016, and has received a Kenneth Rainin Foundation Innovator Award and a Pew Biomedical Scholar Award for her continued work on the influence of the microbiota on viral infection. Her lab now focuses on the role of the microbiota in regulating infection by enteric viruses norovirus and rotavirus, as well as in modulating mucosal vaccine responses to rotavirus and HIV vaccines.
-
Kelly Byrnes-Blake
PhD in pharmacology
Scientist in pharmacokinetics
16 years supporting drug research and development as a pharmacokineticist
Kelly Byrnes-Blake has been a pharmacokineticist supporting drug research and development for over 16 years. Kelly earned a PhD in pharmacology, with specific training in pharmacokinetics, from the University of Arkansas for Medical Sciences in 2001 where she studied antibody-based therapies for drugs of abuse. She also holds a dual bachelor’s degree in Biology and Mathematics from Western Washington University.
After obtaining her PhD, Kelly worked as an Investigator at GlaxoSmithKline in a drug discovery/lead optimization PK group where she directed preclinical PK studies and represented the group on multidisciplinary project development teams. She then worked for 10 years at ZymoGenetics, a Seattle biotech company, first as a Scientist, and later as the head of PK. In these roles she supported several protein-based therapeutic projects from early research through IND-enabling studies and into Phase 1 and 2 clinical trials. Kelly supported the development of growth factors, cytokines, as well as monoclonal antibodies and Fc-fusion proteins.
PhD in pharmacology
Scientist in pharmacokinetics
16 years supporting drug research and development as a pharmacokineticist
Kelly Byrnes-Blake has been a pharmacokineticist supporting drug research and development for over 16 years. Kelly earned a PhD in pharmacology, with specific training in pharmacokinetics, from the University of Arkansas for Medical Sciences in 2001 where she studied antibody-based therapies for drugs of abuse. She also holds a dual bachelor’s degree in Biology and Mathematics from Western Washington University.
After obtaining her PhD, Kelly worked as an Investigator at GlaxoSmithKline in a drug discovery/lead optimization PK group where she directed preclinical PK studies and represented the group on multidisciplinary project development teams. She then worked for 10 years at ZymoGenetics, a Seattle biotech company, first as a Scientist, and later as the head of PK. In these roles she supported several protein-based therapeutic projects from early research through IND-enabling studies and into Phase 1 and 2 clinical trials. Kelly supported the development of growth factors, cytokines, as well as monoclonal antibodies and Fc-fusion proteins.
